Celltrion Becomes First to Acquire U.S. Interchangeability Status for Truxima
RegulatoryapprovedTruximaPositive
AI Analysis
Summary
Celltrion obtained FDA Interchangeability status for Truxima (rituximab), becoming the first rituximab biosimilar to achieve this designation, enabling it to be substituted for the reference product without patient or physician intervention.
Outcome Details
FDA granted Interchangeability status for Truxima (rituximab), making it the first rituximab biosimilar to achieve this designation
Importance:8/10
Sentiment:
0.90
FDA approvalinterchangeabilitybiosimilarrituximabblood cancer
Read the original article
Published by Drugs.com New Drug Approvals on July 1, 2026 4:07 AM